<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01488019</url>
  </required_header>
  <id_info>
    <org_study_id>201-085</org_study_id>
    <nct_id>NCT01488019</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate) Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dey</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multi-center, randomized, placebo-controlled study to evaluate the long-term
      safety of Perforomist® inhalation therapy in subjects with Chronic Obstructive Pulmonary
      Disease (COPD). Individual participation is approximately 54 weeks, including 52 weeks of
      double-blind treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      None provided.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With a Primary Event of Respiratory Death, First COPD-Related Emergency Room Visit, or First COPD Exacerbation-Related Hospitalisation</measure>
    <time_frame>0 to 52 weeks</time_frame>
    <description>The primary endpoint was the combined incidence of respiratory death, first COPD-related ER visit or first COPD exacerbation-related hospitalization (whichever occurred first from the time of randomization to the end of the study). The time-to-first event was measured and analyzed in units of weeks and was summarized by treatment for subjects in the Safety Set. An independent Mortality Adjudication Board was used to evaluate all deaths that occurred in the study and for assigning cause of death and COPD-relatedness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Kaplan-Meier Probability of Respiratory Death, First COPD-Related Emergency Room Visit, or First COPD Exacerbation-Related Hospitalisation at 52 Weeks</measure>
    <time_frame>0 to 52 weeks</time_frame>
    <description>The primary endpoint was the combined incidence of respiratory death, first COPD-related ER visit or first COPD exacerbation-related hospitalization (whichever occurred first from the time of randomization to the end of the study). The time-to-first event was measured and analyzed in units of weeks and was summarized by treatment for subjects in the Safety Set. An independent Mortality Adjudication Board was used to evaluate all deaths that occurred in the study and for assigning cause of death and COPD-relatedness.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Summary of All Cause Mortality, COPD Related Mortality and Respiratory Related Mortality</measure>
    <time_frame>0 to 52 weeks</time_frame>
    <description>An independent Mortality Adjudication Board was used to evaluate all deaths that occurred in the study and for assigning cause of death and COPD-relatedness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual Components of the Primary Composite Endpoint - First COPD-related ER Visit and First COPD Exacerbation-Related Hospitalization</measure>
    <time_frame>0 to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Protocol-Defined COPD Exacerbation</measure>
    <time_frame>0 to 52 weeks</time_frame>
    <description>COPD exacerbations were defined as events in the natural course of disease characterized by an increase from baseline in two of the following symptoms: dyspnea, cough, and sputum production that was beyond normal day-to-day variations, was acute in onset, that persisted for at least two consecutive days, and that warranted a change in their regular medication. The change could be either the initiation of additional treatment(s) or the intensification of a treatment the subject was already receiving, and the change must have been specifically to address the exacerbation event. COPD exacerbations occurring after the time of withdrawal or completion of the study were not included.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Probability of Protocol Defined COPD Exacerbation at 52 Weeks</measure>
    <time_frame>0 to 52 weeks</time_frame>
    <description>COPD exacerbations were defined as events in the natural course of disease characterized by an increase from baseline in two of the following symptoms: dyspnea, cough, and sputum production that was beyond normal day-to-day variations, was acute in onset, that persisted for at least two consecutive days, and that warranted a change in their regular medication.The change could be either the initiation of additional treatment(s) or the intensification of a treatment the subject was already receiving, and the change must have been specifically to address the exacerbation event. COPD exacerbations occurring after the time of withdrawal or completion of the study were not included.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 Changes From Baseline at Months 3, 6, 9 and 12</measure>
    <time_frame>On treatment at months 3, 6, 9 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC Changes From Baseline at Months 3, 6, 9 and 12</measure>
    <time_frame>On treatment at months 3, 6, 9 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IC Changes From Baseline at Months 3, 6, 9 and 12</measure>
    <time_frame>On treatment at months 3, 6, 9 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saint Georges Respiratory Questionnaire Scores: Changes From Baseline at Months 3, 6, 9, 12</measure>
    <time_frame>On treatment at months 3, 6, 9 and 12</time_frame>
    <description>Saint Georges Respiratory Questionnaire comprises 50 items in 3 sections, Symptoms, Activity, Impact, measuring health status in chronic airflow limitation. Symptoms captures level of symptomatology. Activity and Impact responses are either &quot;yes&quot; or &quot;no&quot;. Scoring is from 0 to 100; 0 = no life quality impairment. A summary score for all items is calculated and ranges from 0 to 100, where 0 indicates best possible health status, 100 represents worst possible health status. Scores are calculated using weights attached to each item in the questionnaire - 4 unit changes are clinically meaningful.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transition Dyspnea Index</measure>
    <time_frame>On treatment at months 3, 6, 9 and 12</time_frame>
    <description>The Transition Dyspnea Index (TDI) measures changes in dyspnea severity from the baseline as established by the BDI. It has 3 components: change in functional impairment, change in magnitude of task, and change in magnitude of effort, and each component is rated on a scale ranging from -3 (major deterioration) to +3 (major improvement). The 3 components are summed to provide a total score ranging from -9 to +9. The lower the score, the more deterioration in severity of dyspnea.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Care Utilization and Economic Impact - Number of Emergency Department Visits</measure>
    <time_frame>0 to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Subjects Requiring Intubation or Non-Invasive Ventilation</measure>
    <time_frame>0 to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue Medication Usage</measure>
    <time_frame>0 to 52 weeks</time_frame>
    <description>Number of puffs of rescue medication (albuterol pMDI) used per day</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1071</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Perforomist, nebulization, COPD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Perforomist-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perforomist-Placebo</intervention_name>
    <description>Placebo vehicle, 2mL, twice daily for 52 weeks</description>
    <arm_group_label>Perforomist-Placebo</arm_group_label>
    <other_name>Perforomist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perforomist, nebulization, COPD</intervention_name>
    <description>Perforomist, 20 mcg/2 mL, twice daily for 52 weeks</description>
    <arm_group_label>Perforomist, nebulization, COPD</arm_group_label>
    <other_name>Formoterol fumarate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able to understand the study requirements, provide written informed consent, and agree
             to abide by the study protocol and its restrictions

          2. Male and female subjects at least 40 years of age with a medical diagnosis of COPD
             (i.e. persistent presence of dyspnea, cough or sputum production and a history of
             exposure to risk factors for the disease, such as tobacco smoke)

          3. A current or prior history of at least 10 pack-years of cigarette smoking and a
             baseline breathlessness severity grade of &gt;=2 (Modified Medical Research Council
             [MMRC] Dyspnea Scale Score) at randomization.

          4. Women of child-bearing potential (WOCBP) must have a negative pregnancy test at the
             screening visit and agree to avoid becoming pregnant for the duration of study by
             using adequate contraception at study entry and throughout the trial. WOCBP will be
             advised to notify the Investigator of any change in their pregnancy status. WOCBP
             include: any female who has experienced menarche and is not post-menopausal (defined
             as amenorrhea for at least 12 consecutive months), or has not undergone surgical
             sterilization (hysterectomy, bilateral oophorectomy, or bilateral tubal ligation).
             Women who are using acceptable contraceptive medications or devices to prevent
             pregnancy or practicing abstinence or where partner is sterile (e.g., vasectomy) will
             be considered WOCBP.

          5. Able to complete all aspects of the study through the end of the study, including all
             visits and tests, and self-administration of study medications.

        Exclusion Criteria:

          1. A medical diagnosis of asthma. Indication of a past history of asthma that is deemed
             inaccurate to a subject's current condition by the Investigator must be adequately
             addressed in the medical history.

          2. Clinically significant abnormal chest x-ray (CXR) (within the past 12 months)
             diagnostic of active/significant disease other than COPD.

          3. Evidence of any unstable or clinically significant hematopoietic, malignant,
             cardiovascular, hepatic, renal, neurologic, psychiatric, autoimmune disorder, or
             condition or disease other than COPD that, in the opinion of the Investigator, could
             place the subject at increased risk of complications, interfere with study
             participation, or confound any of the study objectives.

          4. Subjects who had radiation or chemotherapy within the previous 12 months.

          5. An abnormal laboratory test at screening deemed clinically significant and
             exclusionary by the Investigator.

          6. A history of hypersensitivity to study drugs or their components, including albuterol
             rescue.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dik Ng</last_name>
    <role>Study Director</role>
    <affiliation>Mylan Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chandar Abboy</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2011</study_first_submitted>
  <study_first_submitted_qc>December 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2011</study_first_posted>
  <results_first_submitted>March 21, 2017</results_first_submitted>
  <results_first_submitted_qc>May 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 12, 2017</results_first_posted>
  <last_update_submitted>May 11, 2017</last_update_submitted>
  <last_update_submitted_qc>May 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Perforomist Inhalation Solution</title>
          <description>Active
Perforomist Inhalation Solution, 20 mcg/2 mL, twice daily nebulization for 52 weeks</description>
        </group>
        <group group_id="P2">
          <title>Matching Placebo</title>
          <description>Placebo
Perforomist Matching Placebo: placebo vehicle, 2mL, twice daily nebulization for 52 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="541"/>
                <participants group_id="P2" count="530"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="294"/>
                <participants group_id="P2" count="226"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="247"/>
                <participants group_id="P2" count="304"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Set</population>
      <group_list>
        <group group_id="B1">
          <title>Perforomist Inhalation Solution</title>
          <description>Active
Perforomist Inhalation Solution, 20mcg/2 mL, twice daily nebulization for 52 weeks</description>
        </group>
        <group group_id="B2">
          <title>Matching Placebo</title>
          <description>Placebo
Perforomist Matching Placebo: placebo vehicle, 2mL, twice daily nebulization for 52 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="541"/>
            <count group_id="B2" value="530"/>
            <count group_id="B3" value="1071"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="541"/>
                    <count group_id="B2" value="530"/>
                    <count group_id="B3" value="1071"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.7" spread="9.01"/>
                    <measurement group_id="B2" value="62.5" spread="9.17"/>
                    <measurement group_id="B3" value="62.6" spread="9.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="541"/>
                    <count group_id="B2" value="530"/>
                    <count group_id="B3" value="1071"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="285"/>
                    <measurement group_id="B2" value="267"/>
                    <measurement group_id="B3" value="552"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="256"/>
                    <measurement group_id="B2" value="263"/>
                    <measurement group_id="B3" value="519"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="541"/>
                    <count group_id="B2" value="530"/>
                    <count group_id="B3" value="1071"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="512"/>
                    <measurement group_id="B2" value="504"/>
                    <measurement group_id="B3" value="1016"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="541"/>
                    <count group_id="B2" value="530"/>
                    <count group_id="B3" value="1071"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="483"/>
                    <measurement group_id="B2" value="478"/>
                    <measurement group_id="B3" value="961"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="541"/>
                    <count group_id="B2" value="530"/>
                    <count group_id="B3" value="1071"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="541"/>
                    <count group_id="B2" value="530"/>
                    <count group_id="B3" value="1071"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian or Pacific Islander</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="541"/>
                    <count group_id="B2" value="530"/>
                    <count group_id="B3" value="1071"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="541"/>
                    <count group_id="B2" value="530"/>
                    <count group_id="B3" value="1071"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="541"/>
                    <count group_id="B2" value="530"/>
                    <count group_id="B3" value="1071"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="541"/>
                    <measurement group_id="B2" value="530"/>
                    <measurement group_id="B3" value="1071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Screening COPD Severity (GOLD) n (%)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Moderate (% Predicted FEV1 50 to &lt;80%)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="541"/>
                    <count group_id="B2" value="530"/>
                    <count group_id="B3" value="1071"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="274"/>
                    <measurement group_id="B2" value="273"/>
                    <measurement group_id="B3" value="547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe (% Predicted FEV1 30 to &lt;50%)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="541"/>
                    <count group_id="B2" value="530"/>
                    <count group_id="B3" value="1071"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="261"/>
                    <measurement group_id="B2" value="250"/>
                    <measurement group_id="B3" value="511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Severe (% Predicted FEV1 &lt;30%)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="541"/>
                    <count group_id="B2" value="530"/>
                    <count group_id="B3" value="1071"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Reported/Unknown</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="541"/>
                    <count group_id="B2" value="530"/>
                    <count group_id="B3" value="1071"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline FEV1</title>
          <description>Forced expiratory volume in one second</description>
          <population>Only subjects with data collected and valid measurements included</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="539"/>
                    <count group_id="B2" value="526"/>
                    <count group_id="B3" value="1065"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.2494" spread="0.47593"/>
                    <measurement group_id="B2" value="1.2926" spread="0.50496"/>
                    <measurement group_id="B3" value="1.2707" spread="0.49073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline % Predicted FEV1</title>
          <description>Forced expiratory volume in one second, percent of predicted NHANES III reference values</description>
          <population>Only subjects with data collected and valid measurements included</population>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="539"/>
                    <count group_id="B2" value="526"/>
                    <count group_id="B3" value="1065"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.82" spread="12.646"/>
                    <measurement group_id="B2" value="44.89" spread="13.787"/>
                    <measurement group_id="B3" value="44.35" spread="13.226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline FVC</title>
          <description>Forced vital capacity</description>
          <population>Only subjects with data collected and valid measurements included</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="539"/>
                    <count group_id="B2" value="526"/>
                    <count group_id="B3" value="1065"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.4276" spread="0.74347"/>
                    <measurement group_id="B2" value="2.4740" spread="0.78394"/>
                    <measurement group_id="B3" value="2.451" spread="0.76373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline IC</title>
          <description>Inspiratory Capacity</description>
          <population>Only subjects with data collected and valid measurements included</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="522"/>
                    <count group_id="B2" value="514"/>
                    <count group_id="B3" value="1036"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.9458" spread="0.66598"/>
                    <measurement group_id="B2" value="1.9783" spread="0.66897"/>
                    <measurement group_id="B3" value="1.9619" spread="0.66734"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Pack Years</title>
          <units>Pack Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="541"/>
                    <count group_id="B2" value="530"/>
                    <count group_id="B3" value="1071"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.37" spread="26.176"/>
                    <measurement group_id="B2" value="50.87" spread="27.912"/>
                    <measurement group_id="B3" value="49.60" spread="27.066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Pack Years</title>
          <units>Pack Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="541"/>
                    <count group_id="B2" value="530"/>
                    <count group_id="B3" value="1071"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41" lower_limit="10.0" upper_limit="184.0"/>
                    <measurement group_id="B2" value="44.00" lower_limit="10.0" upper_limit="232.0"/>
                    <measurement group_id="B3" value="43.00" lower_limit="10.0" upper_limit="232.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Status n (%)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ex-smoker</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="541"/>
                    <count group_id="B2" value="530"/>
                    <count group_id="B3" value="1071"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="259"/>
                    <measurement group_id="B2" value="252"/>
                    <measurement group_id="B3" value="511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current Smoker</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="541"/>
                    <count group_id="B2" value="530"/>
                    <count group_id="B3" value="1071"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="282"/>
                    <measurement group_id="B2" value="278"/>
                    <measurement group_id="B3" value="560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Saint Georges Respiratory Questionnaire Score</title>
          <description>Saint Georges Respiratory Questionnaire comprises 50 items in 3 sections (Symptoms, Activity, Impact) measuring health status in chronic airflow limitation. Symptoms captures level of symptomatology. Activity and Impact responses are either “yes” or “no”. Scoring is from 0 to 100; 0 = no life quality impairment. A summary score for all items is calculated and ranges from 0 to 100, where 0 indicates best possible health status, 100 represents worst possible health status. Scores are calculated using weights attached to each item in the questionnaire - 4 unit changes are clinically meaningful.</description>
          <population>Only subjects with data collected and valid measurements included</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="536"/>
                    <count group_id="B2" value="529"/>
                    <count group_id="B3" value="1065"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.429" spread="16.9607"/>
                    <measurement group_id="B2" value="52.550" spread="16.9953"/>
                    <measurement group_id="B3" value="52.992" spread="16.9756"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Dyspnea Index</title>
          <description>The Baseline Dyspnea Index (BDI) is an interviewer-administered rating of severity of dyspnea at baseline. It has 3 components: functional impairment, magnitude of task, and magnitude of effort, and each component is rated on a graded scale from 0 (very severe) to 4 (no impairment). The 3 components are summed to provide a total score ranging from 0 to 12. The lower the score, the worse the severity of dyspnea.</description>
          <population>Only subjects with data collected and valid measurements included</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="539"/>
                    <count group_id="B2" value="528"/>
                    <count group_id="B3" value="1067"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.1" spread="1.99"/>
                    <measurement group_id="B2" value="6.2" spread="1.99"/>
                    <measurement group_id="B3" value="6.2" spread="1.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With a Primary Event of Respiratory Death, First COPD-Related Emergency Room Visit, or First COPD Exacerbation-Related Hospitalisation</title>
        <description>The primary endpoint was the combined incidence of respiratory death, first COPD-related ER visit or first COPD exacerbation-related hospitalization (whichever occurred first from the time of randomization to the end of the study). The time-to-first event was measured and analyzed in units of weeks and was summarized by treatment for subjects in the Safety Set. An independent Mortality Adjudication Board was used to evaluate all deaths that occurred in the study and for assigning cause of death and COPD-relatedness.</description>
        <time_frame>0 to 52 weeks</time_frame>
        <population>Safety Set - All subjects who were randomized to treatment and took at least one dose of study medication. Subjects were analyzed according to the actual treatment they received for the majority of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Perforomist Inhalation Solution</title>
            <description>Active
Perforomist Inhalation Solution, 20 mcg/2 mL, twice daily nebulization for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Matching Placebo</title>
            <description>Placebo
Perforomist Matching Placebo: placebo vehicle, 2mL, twice daily nebulization for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a Primary Event of Respiratory Death, First COPD-Related Emergency Room Visit, or First COPD Exacerbation-Related Hospitalisation</title>
          <description>The primary endpoint was the combined incidence of respiratory death, first COPD-related ER visit or first COPD exacerbation-related hospitalization (whichever occurred first from the time of randomization to the end of the study). The time-to-first event was measured and analyzed in units of weeks and was summarized by treatment for subjects in the Safety Set. An independent Mortality Adjudication Board was used to evaluate all deaths that occurred in the study and for assigning cause of death and COPD-relatedness.</description>
          <population>Safety Set - All subjects who were randomized to treatment and took at least one dose of study medication. Subjects were analyzed according to the actual treatment they received for the majority of the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="541"/>
                <count group_id="O2" value="530"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The hazard ratio and 90% two-sided confidence interval for the hazard ratio comparing Perforomist to placebo were estimated. Non-inferiority was declared if the upper limit of the two-sided 90% confidence interval was wholly less than 1.5.</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.965</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.711</ci_lower_limit>
            <ci_upper_limit>1.308</ci_upper_limit>
            <estimate_desc>Hazard Ratio was calculated as Perforomist Inhalation Solution vs Placebo. The non-inferiority margin for the hazard ratio is 1.5.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Kaplan-Meier Probability of Respiratory Death, First COPD-Related Emergency Room Visit, or First COPD Exacerbation-Related Hospitalisation at 52 Weeks</title>
        <description>The primary endpoint was the combined incidence of respiratory death, first COPD-related ER visit or first COPD exacerbation-related hospitalization (whichever occurred first from the time of randomization to the end of the study). The time-to-first event was measured and analyzed in units of weeks and was summarized by treatment for subjects in the Safety Set. An independent Mortality Adjudication Board was used to evaluate all deaths that occurred in the study and for assigning cause of death and COPD-relatedness.</description>
        <time_frame>0 to 52 weeks</time_frame>
        <population>Safety Set - All subjects who were randomized to treatment and took at least one dose of study medication. Subjects were analyzed according to the actual treatment they received for the majority of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Perforomist Inhalation Solution</title>
            <description>Active
Perforomist Inhalation Solution, 20 mcg/2 mL, twice daily nebulization for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Matching Placebo</title>
            <description>Placebo
Perforomist Matching Placebo: placebo vehicle, 2mL, twice daily nebulization for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Probability of Respiratory Death, First COPD-Related Emergency Room Visit, or First COPD Exacerbation-Related Hospitalisation at 52 Weeks</title>
          <description>The primary endpoint was the combined incidence of respiratory death, first COPD-related ER visit or first COPD exacerbation-related hospitalization (whichever occurred first from the time of randomization to the end of the study). The time-to-first event was measured and analyzed in units of weeks and was summarized by treatment for subjects in the Safety Set. An independent Mortality Adjudication Board was used to evaluate all deaths that occurred in the study and for assigning cause of death and COPD-relatedness.</description>
          <population>Safety Set - All subjects who were randomized to treatment and took at least one dose of study medication. Subjects were analyzed according to the actual treatment they received for the majority of the study.</population>
          <units>percent</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="541"/>
                <count group_id="O2" value="530"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5"/>
                    <measurement group_id="O2" value="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of All Cause Mortality, COPD Related Mortality and Respiratory Related Mortality</title>
        <description>An independent Mortality Adjudication Board was used to evaluate all deaths that occurred in the study and for assigning cause of death and COPD-relatedness.</description>
        <time_frame>0 to 52 weeks</time_frame>
        <population>Safety Set - All subjects who were randomized to treatment and took at least one dose of study medication. Subjects were analyzed according to the actual treatment they received for the majority of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Perforomist Inhalation Solution</title>
            <description>Active
Perforomist Inhalation Solution, 20 mcg/2 mL, twice daily nebulization for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Matching Placebo</title>
            <description>Placebo
Perforomist Matching Placebo: placebo vehicle, 2mL, twice daily nebulization for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of All Cause Mortality, COPD Related Mortality and Respiratory Related Mortality</title>
          <description>An independent Mortality Adjudication Board was used to evaluate all deaths that occurred in the study and for assigning cause of death and COPD-relatedness.</description>
          <population>Safety Set - All subjects who were randomized to treatment and took at least one dose of study medication. Subjects were analyzed according to the actual treatment they received for the majority of the study.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="541"/>
                <count group_id="O2" value="530"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Incidence of All Cause Mortalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Incidence of Respiratory Related Mortalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Incidence of COPD Related Mortalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual Components of the Primary Composite Endpoint - First COPD-related ER Visit and First COPD Exacerbation-Related Hospitalization</title>
        <time_frame>0 to 52 weeks</time_frame>
        <population>Safety Set - All subjects who were randomized to treatment and took at least one dose of study medication. Subjects were analyzed according to the actual treatment they received for the majority of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Perforomist Inhalation Solution</title>
            <description>Active
Perforomist Inhalation Solution, 20 mcg/2 mL, twice daily nebulization for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Matching Placebo</title>
            <description>Placebo
Perforomist Matching Placebo: placebo vehicle, 2mL, twice daily nebulization for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Individual Components of the Primary Composite Endpoint - First COPD-related ER Visit and First COPD Exacerbation-Related Hospitalization</title>
          <population>Safety Set - All subjects who were randomized to treatment and took at least one dose of study medication. Subjects were analyzed according to the actual treatment they received for the majority of the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="541"/>
                <count group_id="O2" value="530"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with a COPD­ related ER Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with a COPD-Related Hospitalization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Protocol-Defined COPD Exacerbation</title>
        <description>COPD exacerbations were defined as events in the natural course of disease characterized by an increase from baseline in two of the following symptoms: dyspnea, cough, and sputum production that was beyond normal day-to-day variations, was acute in onset, that persisted for at least two consecutive days, and that warranted a change in their regular medication. The change could be either the initiation of additional treatment(s) or the intensification of a treatment the subject was already receiving, and the change must have been specifically to address the exacerbation event. COPD exacerbations occurring after the time of withdrawal or completion of the study were not included.</description>
        <time_frame>0 to 52 weeks</time_frame>
        <population>Safety Set - All subjects who were randomized to treatment and took at least one dose of study medication. Subjects were analyzed according to the actual treatment they received for the majority of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Perforomist Inhalation Solution</title>
            <description>Active
Perforomist Inhalation Solution, 20 mcg/2 mL, twice daily nebulization for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Matching Placebo</title>
            <description>Placebo
Perforomist Matching Placebo: placebo vehicle, 2mL, twice daily nebulization for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Protocol-Defined COPD Exacerbation</title>
          <description>COPD exacerbations were defined as events in the natural course of disease characterized by an increase from baseline in two of the following symptoms: dyspnea, cough, and sputum production that was beyond normal day-to-day variations, was acute in onset, that persisted for at least two consecutive days, and that warranted a change in their regular medication. The change could be either the initiation of additional treatment(s) or the intensification of a treatment the subject was already receiving, and the change must have been specifically to address the exacerbation event. COPD exacerbations occurring after the time of withdrawal or completion of the study were not included.</description>
          <population>Safety Set - All subjects who were randomized to treatment and took at least one dose of study medication. Subjects were analyzed according to the actual treatment they received for the majority of the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="541"/>
                <count group_id="O2" value="530"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Probability of Protocol Defined COPD Exacerbation at 52 Weeks</title>
        <description>COPD exacerbations were defined as events in the natural course of disease characterized by an increase from baseline in two of the following symptoms: dyspnea, cough, and sputum production that was beyond normal day-to-day variations, was acute in onset, that persisted for at least two consecutive days, and that warranted a change in their regular medication.The change could be either the initiation of additional treatment(s) or the intensification of a treatment the subject was already receiving, and the change must have been specifically to address the exacerbation event. COPD exacerbations occurring after the time of withdrawal or completion of the study were not included.</description>
        <time_frame>0 to 52 weeks</time_frame>
        <population>Safety Set - All subjects who were randomized to treatment and took at least one dose of study medication. Subjects were analyzed according to the actual treatment they received for the majority of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Perforomist Inhalation Solution</title>
            <description>Active
Perforomist Inhalation Solution, 20 mcg/2 mL, twice daily nebulization for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Matching Placebo</title>
            <description>Placebo
Perforomist Matching Placebo: placebo vehicle, 2mL, twice daily nebulization for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Probability of Protocol Defined COPD Exacerbation at 52 Weeks</title>
          <description>COPD exacerbations were defined as events in the natural course of disease characterized by an increase from baseline in two of the following symptoms: dyspnea, cough, and sputum production that was beyond normal day-to-day variations, was acute in onset, that persisted for at least two consecutive days, and that warranted a change in their regular medication.The change could be either the initiation of additional treatment(s) or the intensification of a treatment the subject was already receiving, and the change must have been specifically to address the exacerbation event. COPD exacerbations occurring after the time of withdrawal or completion of the study were not included.</description>
          <population>Safety Set - All subjects who were randomized to treatment and took at least one dose of study medication. Subjects were analyzed according to the actual treatment they received for the majority of the study.</population>
          <units>percent</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="541"/>
                <count group_id="O2" value="530"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.7"/>
                    <measurement group_id="O2" value="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 Changes From Baseline at Months 3, 6, 9 and 12</title>
        <time_frame>On treatment at months 3, 6, 9 and 12</time_frame>
        <population>Full Analysis Set: all subjects randomized who took at least one dose of study medication. Subjects were analyzed according to their assigned treatment at randomization. Only subjects with data collected and valid measurements included</population>
        <group_list>
          <group group_id="O1">
            <title>Perforomist Inhalation Solution</title>
            <description>Active
Perforomist Inhalation Solution, 20 mcg/2 mL, twice daily nebulization for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Matching Placebo</title>
            <description>Placebo
Perforomist Matching Placebo: placebo vehicle, 2mL, twice daily nebulization for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Changes From Baseline at Months 3, 6, 9 and 12</title>
          <population>Full Analysis Set: all subjects randomized who took at least one dose of study medication. Subjects were analyzed according to their assigned treatment at randomization. Only subjects with data collected and valid measurements included</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="541"/>
                <count group_id="O2" value="530"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline FEV1: Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="486"/>
                    <count group_id="O2" value="435"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.058" spread="0.0116"/>
                    <measurement group_id="O2" value="0.016" spread="0.0123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline FEV1: Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="366"/>
                    <count group_id="O2" value="293"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.057" spread="0.0130"/>
                    <measurement group_id="O2" value="0.017" spread="0.0143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline FEV1: Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="314"/>
                    <count group_id="O2" value="250"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.050" spread="0.0136"/>
                    <measurement group_id="O2" value="0.029" spread="0.0151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline FEV1: Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="294"/>
                    <count group_id="O2" value="227"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.030" spread="0.0144"/>
                    <measurement group_id="O2" value="0.000" spread="0.0160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC Changes From Baseline at Months 3, 6, 9 and 12</title>
        <time_frame>On treatment at months 3, 6, 9 and 12</time_frame>
        <population>Full Analysis Set: all subjects randomized who took at least one dose of study medication. Subjects were analyzed according to their assigned treatment at randomization. Only subjects with data collected and valid measurements included</population>
        <group_list>
          <group group_id="O1">
            <title>Perforomist Inhalation Solution</title>
            <description>Active
Perforomist Inhalation Solution, 20 mcg/2 mL, twice daily nebulization for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Matching Placebo</title>
            <description>Placebo
Perforomist Matching Placebo: placebo vehicle, 2mL, twice daily nebulization for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>FVC Changes From Baseline at Months 3, 6, 9 and 12</title>
          <population>Full Analysis Set: all subjects randomized who took at least one dose of study medication. Subjects were analyzed according to their assigned treatment at randomization. Only subjects with data collected and valid measurements included</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="541"/>
                <count group_id="O2" value="530"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline FVC: Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="486"/>
                    <count group_id="O2" value="435"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1051" spread="0.40479"/>
                    <measurement group_id="O2" value="0.0062" spread="0.38724"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline FVC: Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="366"/>
                    <count group_id="O2" value="293"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1006" spread="0.38875"/>
                    <measurement group_id="O2" value="-0.0241" spread="0.37124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline FVC: Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="314"/>
                    <count group_id="O2" value="250"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1009" spread="0.39533"/>
                    <measurement group_id="O2" value="-0.0254" spread="0.40947"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline FVC: Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="294"/>
                    <count group_id="O2" value="227"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0645" spread="0.43490"/>
                    <measurement group_id="O2" value="-0.0581" spread="0.38069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IC Changes From Baseline at Months 3, 6, 9 and 12</title>
        <time_frame>On treatment at months 3, 6, 9 and 12</time_frame>
        <population>Full Analysis Set: all subjects randomized who took at least one dose of study medication. Subjects were analyzed according to their assigned treatment at randomization. Only subjects with data collected and valid measurements included</population>
        <group_list>
          <group group_id="O1">
            <title>Perforomist Inhalation Solution</title>
            <description>Active
Perforomist Inhalation Solution, 20 mcg/2 mL, twice daily nebulization for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Matching Placebo</title>
            <description>Placebo
Perforomist Matching Placebo: placebo vehicle, 2mL, twice daily nebulization for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>IC Changes From Baseline at Months 3, 6, 9 and 12</title>
          <population>Full Analysis Set: all subjects randomized who took at least one dose of study medication. Subjects were analyzed according to their assigned treatment at randomization. Only subjects with data collected and valid measurements included</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="541"/>
                <count group_id="O2" value="530"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline IC: Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="467"/>
                    <count group_id="O2" value="420"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0287" spread="0.42478"/>
                    <measurement group_id="O2" value="-0.0119" spread="0.39505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline IC: Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="354"/>
                    <count group_id="O2" value="287"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0440" spread="0.44862"/>
                    <measurement group_id="O2" value="-0.0106" spread="0.43483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline IC: Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="306"/>
                    <count group_id="O2" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1584" spread="1.84290"/>
                    <measurement group_id="O2" value="-0.0118" spread="0.43513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline IC: Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="284"/>
                    <count group_id="O2" value="221"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0477" spread="0.48057"/>
                    <measurement group_id="O2" value="-0.0105" spread="0.44289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Saint Georges Respiratory Questionnaire Scores: Changes From Baseline at Months 3, 6, 9, 12</title>
        <description>Saint Georges Respiratory Questionnaire comprises 50 items in 3 sections, Symptoms, Activity, Impact, measuring health status in chronic airflow limitation. Symptoms captures level of symptomatology. Activity and Impact responses are either “yes” or “no”. Scoring is from 0 to 100; 0 = no life quality impairment. A summary score for all items is calculated and ranges from 0 to 100, where 0 indicates best possible health status, 100 represents worst possible health status. Scores are calculated using weights attached to each item in the questionnaire - 4 unit changes are clinically meaningful.</description>
        <time_frame>On treatment at months 3, 6, 9 and 12</time_frame>
        <population>Full Analysis Set: all subjects randomized who took at least one dose of study medication. Subjects were analyzed according to their assigned treatment at randomization. Only subjects with data collected were included</population>
        <group_list>
          <group group_id="O1">
            <title>Perforomist Inhalation Solution</title>
            <description>Active
Perforomist Inhalation Solution, 20 mcg/2 mL, twice daily nebulization for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Matching Placebo</title>
            <description>Placebo
Perforomist Matching Placebo: placebo vehicle, 2mL, twice daily nebulization for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Saint Georges Respiratory Questionnaire Scores: Changes From Baseline at Months 3, 6, 9, 12</title>
          <description>Saint Georges Respiratory Questionnaire comprises 50 items in 3 sections, Symptoms, Activity, Impact, measuring health status in chronic airflow limitation. Symptoms captures level of symptomatology. Activity and Impact responses are either “yes” or “no”. Scoring is from 0 to 100; 0 = no life quality impairment. A summary score for all items is calculated and ranges from 0 to 100, where 0 indicates best possible health status, 100 represents worst possible health status. Scores are calculated using weights attached to each item in the questionnaire - 4 unit changes are clinically meaningful.</description>
          <population>Full Analysis Set: all subjects randomized who took at least one dose of study medication. Subjects were analyzed according to their assigned treatment at randomization. Only subjects with data collected were included</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="541"/>
                <count group_id="O2" value="530"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline SGRQ Total Score: Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="502"/>
                    <count group_id="O2" value="465"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.252" spread="0.5472"/>
                    <measurement group_id="O2" value="-2.027" spread="0.5727"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline SGRQ Total Score: Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="377"/>
                    <count group_id="O2" value="299"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.329" spread="0.6541"/>
                    <measurement group_id="O2" value="-2.511" spread="0.7156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline SGRQ Total Score: Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="315"/>
                    <count group_id="O2" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.021" spread="0.7022"/>
                    <measurement group_id="O2" value="-2.115" spread="0.7681"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline SGRQ Total Score: Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="294"/>
                    <count group_id="O2" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.453" spread="0.7559"/>
                    <measurement group_id="O2" value="-1.475" spread="0.8345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transition Dyspnea Index</title>
        <description>The Transition Dyspnea Index (TDI) measures changes in dyspnea severity from the baseline as established by the BDI. It has 3 components: change in functional impairment, change in magnitude of task, and change in magnitude of effort, and each component is rated on a scale ranging from -3 (major deterioration) to +3 (major improvement). The 3 components are summed to provide a total score ranging from -9 to +9. The lower the score, the more deterioration in severity of dyspnea.</description>
        <time_frame>On treatment at months 3, 6, 9 and 12</time_frame>
        <population>Full Analysis Set: all subjects randomized who took at least one dose of study medication. Subjects were analyzed according to their assigned treatment at randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Perforomist Inhalation Solution</title>
            <description>Active
Perforomist, nebulization, COPD: Perforomist, 20 mcg/2 mL, twice daily for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Matching Placebo</title>
            <description>Placebo
Perforomist-Placebo: Placebo vehicle, 2mL, twice daily for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Transition Dyspnea Index</title>
          <description>The Transition Dyspnea Index (TDI) measures changes in dyspnea severity from the baseline as established by the BDI. It has 3 components: change in functional impairment, change in magnitude of task, and change in magnitude of effort, and each component is rated on a scale ranging from -3 (major deterioration) to +3 (major improvement). The 3 components are summed to provide a total score ranging from -9 to +9. The lower the score, the more deterioration in severity of dyspnea.</description>
          <population>Full Analysis Set: all subjects randomized who took at least one dose of study medication. Subjects were analyzed according to their assigned treatment at randomization.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="541"/>
                <count group_id="O2" value="530"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="508"/>
                    <count group_id="O2" value="464"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.11"/>
                    <measurement group_id="O2" value="0.0" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="380"/>
                    <count group_id="O2" value="298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.13"/>
                    <measurement group_id="O2" value="0.4" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.14"/>
                    <measurement group_id="O2" value="0.4" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="297"/>
                    <count group_id="O2" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.14"/>
                    <measurement group_id="O2" value="0.6" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Care Utilization and Economic Impact - Number of Emergency Department Visits</title>
        <time_frame>0 to 52 weeks</time_frame>
        <population>Full Analysis Set: all subjects randomized who took at least one dose of study medication. Subjects were analyzed according to their assigned treatment at randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Perforomist Inhalation Solution</title>
            <description>Active
Perforomist Inhalation Solution, 20 mcg/2 mL, twice daily nebulization for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Matching Placebo</title>
            <description>Placebo
Perforomist Matching Placebo: placebo vehicle, 2mL, twice daily nebulization for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Health Care Utilization and Economic Impact - Number of Emergency Department Visits</title>
          <population>Full Analysis Set: all subjects randomized who took at least one dose of study medication. Subjects were analyzed according to their assigned treatment at randomization.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="541"/>
                <count group_id="O2" value="530"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="447"/>
                    <measurement group_id="O2" value="437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Subjects Requiring Intubation or Non-Invasive Ventilation</title>
        <time_frame>0 to 52 weeks</time_frame>
        <population>Full Analysis Set: all subjects randomized who took at least one dose of study medication. Subjects were analyzed according to their assigned treatment at randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Perforomist Inhalation Solution</title>
            <description>Active
Perforomist Inhalation Solution, 20 mcg/2 mL, twice daily nebulization for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Matching Placebo</title>
            <description>Placebo
Perforomist Matching Placebo: placebo vehicle, 2mL, twice daily nebulization for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Subjects Requiring Intubation or Non-Invasive Ventilation</title>
          <population>Full Analysis Set: all subjects randomized who took at least one dose of study medication. Subjects were analyzed according to their assigned treatment at randomization.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="541"/>
                <count group_id="O2" value="530"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rescue Medication Usage</title>
        <description>Number of puffs of rescue medication (albuterol pMDI) used per day</description>
        <time_frame>0 to 52 weeks</time_frame>
        <population>Full Analysis Set: all subjects randomized who took at least one dose of study medication. Subjects were analyzed according to their assigned treatment at randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Perforomist Inhalation Solution</title>
            <description>Active
Perforomist Inhalation Solution, 20 mcg/2 mL, twice daily nebulization for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Matching Placebo</title>
            <description>Placebo
Perforomist Matching Placebo: placebo vehicle, 2mL, twice daily nebulization for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Rescue Medication Usage</title>
          <description>Number of puffs of rescue medication (albuterol pMDI) used per day</description>
          <population>Full Analysis Set: all subjects randomized who took at least one dose of study medication. Subjects were analyzed according to their assigned treatment at randomization.</population>
          <units>Mean Puffs per Day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="541"/>
                <count group_id="O2" value="530"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="530"/>
                    <count group_id="O2" value="515"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.55" spread="2.496"/>
                    <measurement group_id="O2" value="2.52" spread="2.484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Phase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="478"/>
                    <count group_id="O2" value="455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" spread="2.063"/>
                    <measurement group_id="O2" value="2.35" spread="2.521"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Approximately 14 months (date of signature of the Informed Consent Form to 30 days after last dose of study drug)</time_frame>
      <desc>Subject Deaths during the Study:
Perforomist x3 (Neoplasms x2, Cardiac Disorders x1) Placebo x10 (Respiratory, Thoracic and Mediastinal Disorders x1, Neoplasms x2, Cardiac Disorders x5, Infections and Infestations x1, Injury x1)</desc>
      <group_list>
        <group group_id="E1">
          <title>Perforomist Inhalation Solution</title>
          <description>Active
Perforomist Inhalation Solution, 20 mcg/2 mL, twice daily nebulization for 52 weeks</description>
        </group>
        <group group_id="E2">
          <title>Matching Placebo</title>
          <description>Placebo
Perforomist Matching Placebo: placebo vehicle, 2mL, twice daily nebulization for 52 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedRA 15</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="530"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Optic ischaemic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Papilloedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Inguinal hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Hepatitis alcoholic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Lobar Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Bronchitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Bronchitis pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Gallbladder abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Pneumonia klebsiella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Gallbladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified stage III</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer stage III</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Thalamic infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Basal ganglia infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Spondylitic myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Bladder outlet obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Penile necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Priapism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Iliac artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="530"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedRA 15</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="374" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="369" subjects_at_risk="530"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="530"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="530"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="530"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="530"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="530"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD</sub_title>
                <counts group_id="E1" subjects_affected="164" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="145" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="530"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="530"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="530"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dik Ng, PhD, Director Clinical Science</name_or_title>
      <organization>Mylan UK</organization>
      <phone>+44 1304626895</phone>
      <email>dik.ng@mylan.co.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

